Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Pipeline Review, H1 2016

  • ID: 3746938
  • Drug Pipelines
  • Region: Global
  • 29 pages
  • Global Markets Direct
1 of 6
Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Pipeline Review, H1 2016

Summary

‘Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Pipeline Review, H1 2016’, provides in depth analysis on Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) targeted pipeline therapeutics.

The report provides comprehensive information on the Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11)
- The report reviews Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) targeted therapeutics and enlists all their major and minor projects
- The report assesses Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6
List of Tables

List of Figures

Introduction

Report Coverage

Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) Overview

Therapeutics Development

Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Products under Development by Stage of Development

Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Products under Development by Therapy Area

Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Products under Development by Indication

Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Pipeline Products Glance

Early Stage Products

Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Products under Development by Companies

Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Products under Development by Universities/Institutes

Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Molecule Type

Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Companies Involved in Therapeutics Development

Hadasit Medical Research Services & Development Ltd

Upsher-Smith Laboratories, Inc.

Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Drug Profiles

Drugs to Antagonize Protease Activated Receptor-2 for Pancreatitis Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-2pal18S - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Antagonize PAR-1 and PAR-2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PZ-235 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize PAR-2 for Atopic Dermatitis, Inflammatory Bowel Disease and Ulcerative Colitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2016

Pipeline by Upsher-Smith Laboratories, Inc., H1 2016

Dormant Projects, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6
According to our recently published report 'Proteinase-Activated Receptor 2 – Pipeline Review, H1 2016'; Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) pipeline Target constitutes close to 6 molecules. Out of which approximately 3 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the report says; Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) Protease activated receptor 2 (PAR2) also known as coagulation factor II (thrombin) receptor-like 1 (F2RL1) is a protein encoded by the F2RL1 gene. PARs (protease-activated receptors) are G-protein-coupled receptors for proteases from the circulation, inflammatory cells and epithelial tissues. PAR2 plays an important role in inflammation and pain. Pancreatic (trypsin I and II) and extrapancreatic (trypsin IV) trypsins, mast cell tryptase and coagulation factors VIIa and Xa cleave and activate PAR 2.

The report 'Proteinase-Activated Receptor 2 – Pipeline Review, H1 2016' outlays comprehensive information on the Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Proteinase-Activated Receptor 2 (Coagulation Factor II Receptor-Like 1 or G-Protein Coupled Receptor 11 or Thrombin Receptor-Like 1 or F2RL1 or GPR11) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Preclinical stages are 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Note: Product cover images may vary from those shown
5 of 6
Hadasit Medical Research Services & Development Ltd
Upsher-Smith Laboratories, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll